Cargando…
The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567236/ https://www.ncbi.nlm.nih.gov/pubmed/22810506 http://dx.doi.org/10.1038/leu.2012.209 |
| _version_ | 1782258684343091200 |
|---|---|
| author | Matutes, E Bosanquet, A G Wade, R Richards, S M Else, M Catovsky, D |
| author_facet | Matutes, E Bosanquet, A G Wade, R Richards, S M Else, M Catovsky, D |
| author_sort | Matutes, E |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3567236 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-35672362013-02-08 The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry Matutes, E Bosanquet, A G Wade, R Richards, S M Else, M Catovsky, D Leukemia Letter to the Editor Nature Publishing Group 2013-02 2012-08-10 /pmc/articles/PMC3567236/ /pubmed/22810506 http://dx.doi.org/10.1038/leu.2012.209 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
| spellingShingle | Letter to the Editor Matutes, E Bosanquet, A G Wade, R Richards, S M Else, M Catovsky, D The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry |
| title | The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry |
| title_full | The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry |
| title_fullStr | The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry |
| title_full_unstemmed | The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry |
| title_short | The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry |
| title_sort | use of individualized tumor response testing in treatment selection: second randomization results from the lrf cll4 trial and the predictive value of the test at trial entry |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567236/ https://www.ncbi.nlm.nih.gov/pubmed/22810506 http://dx.doi.org/10.1038/leu.2012.209 |
| work_keys_str_mv | AT matutese theuseofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT bosanquetag theuseofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT wader theuseofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT richardssm theuseofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT elsem theuseofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT catovskyd theuseofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT matutese useofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT bosanquetag useofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT wader useofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT richardssm useofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT elsem useofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry AT catovskyd useofindividualizedtumorresponsetestingintreatmentselectionsecondrandomizationresultsfromthelrfcll4trialandthepredictivevalueofthetestattrialentry |